Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2

OBJECTIVES: Describe efficacy and safety of 3 years of adalimumab treatment in patients with peripheral spondyloarthritis (pSpA) and identify predictors of remission. METHODS: Patients with pSpA were randomised to adalimumab 40 mg every other week or placebo for 12 weeks; a 144-week open-label exten...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Van den Bosch, Filip, Mease, Philip J, Sieper, Joachim, Baeten, Dominique L, Xia, Yinglin, Chen, Su, Pangan, Aileen L, Song, In-Ho
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Spondyloarthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845429/
https://ncbi.nlm.nih.gov/pubmed/29531780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000566
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados